Can Hadlima be used to treat juvenile idiopathic arthritis?
Hadlima, which contains the drug adalimumab, is a tumor necrosis factor (TNF) blocker approved by the FDA for specific inflammatory conditions. For juvenile idiopathic arthritis (JIA), it is indicated for reducing signs and symptoms, inhibiting structural damage, and improving physical function in patients who are 2 years of age or older 1.
What the research says
The FDA approval specifically covers the use of Hadlima for moderately to severely active polyarticular juvenile idiopathic arthritis in the pediatric population 1. This approval is based on its ability to reduce disease activity and prevent joint damage in this specific group of children 1.
Other research highlights the complexity of treating JIA. For instance, studies using machine learning models on registry data show that predicting disease progression remains challenging, even with advanced therapy 3. Additionally, trials of other drugs like baricitinib in pediatric JIA patients with uveitis have shown limited efficacy, suggesting that not all treatments work for every patient 4.
What to ask your doctor
- Is my child's specific type of juvenile idiopathic arthritis covered by the FDA approval for Hadlima?
- What are the signs and symptoms that indicate my child has moderately to severely active disease?
- How will we measure if Hadlima is reducing structural damage and improving physical function?
- Are there any limitations regarding patients who have previously lost response to or were intolerant to TNF blockers?
This question is drawn from common patient questions about Rheumatology and answered using cited medical research. We do not provide individualized advice.